Pfizer Vaccine Executive Moves to Rival GlaxoSmithKline 

The high-profile industry move comes as Pfizer and other vaccine makers scramble to assess how their shots will stand up to a new variant of the coronavirus that causes Covid-19.

Facebook Told to Sell Giphy by U.K. Regulator 

The U.K.'s top competition regulator directed Meta Platforms, formerly Facebook, to sell social-media animated-images company Giphy, saying its acquisition could limit competition among platforms and U.K. advertisers.

Glencore Faces Call From Activist to Sell Coal Assets 

The commodities giant is the last of the world's large miners to retain a presence in thermal coal, a currently lucrative business but one seen by some as harmful to the environment.

Zara Parent Elevates Founder's Daughter to Chairwoman 

Zara's parent company said it had appointed the daughter of the retailer's founder as its new chairwoman, placing a little-known 37-year-old atop one of the world's largest fashion chains.

KKR, Wells Fargo Look to Expand at Manhattan's Hudson Yards 

High-end office space-with amenities such as outdoor terraces, game rooms and superior ventilation systems-is still in demand as companies try to lure back remote workers and retain talent.

SoftBank Bets on Asian Metaverse Platform Selling Digital Gucci, Dior 

SoftBank is investing $150 million in a South Korean platform that has amassed a large following of young female users by selling high fashion for 3-D avatars.

Covid Antibody Drugs Challenged by Omicron 

Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant, a sign that some therapies might need modifying.

GE's Former Appliance Business Thrives Under Chinese Owners 

Haier Group bought the business from General Electric in 2016 and has been adding jobs and increasing its U.S. market share.

Sapphire Ventures Extends Fundraising Streak With New $2 Billion Haul 

The technology-focused investment firm has been on a fundraising tear this year after wrapping up a previous drive with $1.7 billion in February.

Merck's Covid-19 Pill to Be Reviewed by FDA Advisers 

The panel's endorsement of the antiviral molnupiravir, from Merck and partner Ridgeback, could open the door for FDA authorization before the end of the year.


(END) Dow Jones Newswires

November 30, 2021 09:00 ET (14:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.